Medical/Pharmaceuticals
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
SHANGHAI, April 11, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of HANSIZHUANG (serplulimab), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with chemotherapy for the first-line tr...
2022-04-11 22:07
3634
PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022
DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA ...
2022-04-11 20:00
1773
Global pharma organizations back Turn Biotechnologies to advance its cell rejuvenation program
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas MOUNTAIN VIEW, Calif., April 11, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation com...
2022-04-11 19:00
2831
APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
BOSTON, April 11, 2022 /PRNewswire/ -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy ...
2022-04-11 18:00
3298
InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
SHANGHAI, April 11, 2022 /PRNewswire/ -- InventisBio Co., Ltd., a clinical-stage biotech company based inShanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients. These data are presented in two e-posters at the annual meetin...
2022-04-11 17:37
1390
Singapore-based women's healthcare company marks its first Financial Times ranking
Making its debut on the fourth annual Financial Times ranking of 500 of Asia-Pacific's high-growth companies, INEX Innovate - the pioneering healthcare technology company targeting women's health - is one of only 20 healthcare companies listed in the prestigious line up. SINGAPORE, April 11, 202...
2022-04-11 17:21
2103
Successful Passing Of The EU Qualified Person Audit Of The Group's Manufacturing Facility For ReCOV In Taizhou
TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that, on April 9, 2022, the Company has received the European Union (EU) Qualified Pe...
2022-04-11 16:05
3591
CUHK researchers discover distinct gut microbial signatures for prediction, diagnosis and treatment of long COVID
HONG KONG, April 11, 2022 /PRNewswire/ -- Clinical researchers from The Chinese University of Hong Kong's (CUHK) Faculty of Medicine (CU Medicine) have identified for the first time distinct gut microbiome profiles associated with post-acute COVID-19 syndrome, more commonly known as "long COVID"....
2022-04-11 12:35
3079
Honeywell Teams with AstraZeneca to Develop Next-Generation Respiratory Inhalers That Use Near-Zero Global Warming Potential Propellant
* Next-generation inhaler will use Honeywell's Solstice® Air to reduce greenhouse gas emissions of propellant by up to 99.9 percent vs current inhaler propellant * Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through in...
2022-04-11 09:00
2482
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
The company will present the preclinical data of five novel drug candidates at AACR 2022 (onApril 8-13). Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. SHANGHAI and HONG KONG, April 11, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovativ...
2022-04-11 08:30
4478
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
SAN FRANCISCO and SUZHOU, China, April 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2022-04-11 08:14
3728
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
MELBOURNE, Australia and INDIANAPOLIS, April 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, "Telix", the "Company") today announces that it has entered into a licence agreement with Eli Lilly and Company ("Lilly") under which Telix is granted exclusive worldwide rights to devel...
2022-04-11 06:51
3424
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
-- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022. -- Gannex intends to soon start a Phase III trial in China, the U.S. and European Union after the completion of the Phase II study inChina. -- An epidemiology study in China in 2010 showed that there were a...
2022-04-10 18:20
2844
Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL
Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage bio...
2022-04-09 04:00
4370
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
BEIJING, April 8, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that they have reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ code: BGNE; Hong Kong Stock Exchange code: 06160; Shanghai Stock Exchange code: 688235)on March 10, for licensin...
2022-04-08 21:00
6927
Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand
GAITHERSBURG, Md., and PUNE, India, April 8, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine ...
2022-04-08 21:00
5999
KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce new preclinical data demonstrating the activity of paxalisib in two forms of childhood brain cancer with very high unmet medical need. ...
2022-04-08 20:30
4261
PENTAX Medical Appoints Dr. Klaus Mergener, MD, PhD, MBA as Chief Medical Officer
TOKYO, April 8, 2022 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group,
has announced the appointment of Dr.Klaus Mergener, MD, PhD, MBA to the
position of Chief Medical Officer of PENTAX Lifecare Division (PENTAX Medical)
as ofApril 1st, 2022.
2022-04-08 20:00
5476
TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company's investigational novel drug, EVT801, a selective VEGFR3 ...
2022-04-08 20:00
4041
OliX Pharmaceuticals Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
* Identified knockdown of target genes for the NASH treatment candidate * Reduction of ALT and AST liver marker levels observed in monkey models * Company to present results at the 2022 Academic Symposium of the Korean Endocrine Society SUWON, South Korea, April 8, 2022 /PRNewswire/ -- OliX ...
2022-04-08 20:00
3833
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59273
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
54297
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52334
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
21776
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
17092